Calendrier des promotions ORIC Pharmaceuticals, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., биофармацевтическая компания, работающая на клинической стадии, открывает и разрабатывает методы лечения рака. Основным кандидатом на продукцию компании является ORIC-101, низкомолекулярный антагонист глюкокортикоидного рецептора, который связан с устойчивостью к нескольким классам противораковых средств в различных солидных опухолях. plus de détailsParamètres de base
IPO date
2020-04-24
ISIN
US68622P1093
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 2.31 | 6 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -48.6 | 0 |
| ROE | -54.73 | 0 |
| ROIC | -32.1 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0251 | 10 |
| Debt/Ratio | 0.0116 | 10 |
| Debt/Equity | 0.1276 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 73.1 | 8 |
| Rentabilité EPS, % | -45.43 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 6.35 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 5.14 $ | 0 $ | 0 $ | 23.54 % | 0 % | 0 % |
| common.calendar.number_days.30d | 5.19 $ | 4.73 $ | 6.35 $ | 22.35 % | 0 % | 0 % |
| common.calendar.number_days.90d | 7.56 $ | 4.26 $ | 7.91 $ | -16.01 % | 0 % | 0 % |
| common.calendar.number_days.180d | 9.8 $ | 4.26 $ | 12.54 $ | -35.2 % | 0 % | 0 % |
| common.calendar.number_days.1y | 8.55 $ | 4.26 $ | 12.54 $ | -25.73 % | 0 % | 0 % |
| common.calendar.number_days.3y | 4.48 $ | 2.44 $ | 16.03 $ | 41.74 % | 0 % | 0 % |
| common.calendar.number_days.5y | 34.73 $ | 2.44 $ | 39.8 $ | -81.72 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 2.44 $ | 39.8 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 8.43 $ | 4.26 $ | 12.54 $ | -24.67 % | 0 % | 0 % |
Délit d'initié
Principaux propriétaires
Contenu dans l'ETF
| ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
| Future Tech ETF | 0.07549 | -18.13 | 0.35 |
| Principal Healthcare Innovators ETF | 0.07549 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.01042 | 604.45 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.00869 | 295.15 | 0.25 |
| iShares Morningstar Small-Cap Value ETF | 0.00748 | 173.73 | 0.06 |
| 0,04 | 210,26 | 0,21 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Jacob M. Chacko M.B.A., M.D. | President, CEO & Director | 921.32k | 1979 (46 années) |
| Dr. Edna Chow Maneval | Senior Vice President of Clinical Development | N/A | 1960 (65 années) |
| Dr. Scott W. Lowe Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer | N/A | 1964 (61 année) |
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | 93k | 1957 (68 années) |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel | N/A | 1973 (52 année) |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer | 686.88k | 1967 (58 années) |
| Mr. Daniel Iazzetti | VP & Head of People | N/A | |
| Mr. Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer | 636.91k | 1975 (50 années) |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | 1959 (66 années) |
Informations sur l'entreprise
Adresse: United States, South San Francisco, 240 East Grand Avenue - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: http://www.oricpharma.com
Site web: http://www.oricpharma.com
